Omega Protein Stock Hits New 52-Week High (OME)

NEW YORK ( TheStreet) -- Omega Protein Corporation (NYSE: OME) hit a new 52-week high Wednesday as it traded at $13.85 compared with its previous 52-Week high of $13.78. Omega Protein is changing hands at $13.85 with 129,705 shares traded as of 10:32 a.m. ET. Average volume has been 178,700 shares over the past 30 days.

Omega Protein has a market cap of $238.5 million and is part of the consumer goods sector and food & beverage industry. Shares are up 69.1% year to date as of the close of trading on Tuesday.

Omega Protein Corporation processes, markets, and distributes fish meal and fish oil products in the United States. It produces and sells various protein and oil products derived from menhaden, a species of wild herring-like fish found along the Gulf of Mexico and Atlantic coasts. The company has a P/E ratio of 13.1, equal to the average food & beverage industry P/E ratio and below the S&P 500 P/E ratio of 16.1.
  • Practice your OME trading strategies and win cash in our stock game.

TheStreet Ratings rates Omega Protein as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full Omega Protein Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Dow Tumbles as Trump Ratchets Up China Trade Fight

Dow Tumbles as Trump Ratchets Up China Trade Fight

Netflix Shares Hit All-Time High as Market Flounders

Netflix Shares Hit All-Time High as Market Flounders

Snap Shares Plunge After Cowen Cuts Price Target

Snap Shares Plunge After Cowen Cuts Price Target

FANG Stocks Get Swept Up in Broader Market Selloff

FANG Stocks Get Swept Up in Broader Market Selloff

Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy

Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy